12:00 AM
Feb 04, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

GI-13020: Phase Ia started

GlobeImmune began an open-label, dose-escalation, U.S. Phase Ia trial to evaluate 3 dose levels of GI-13020 given weekly or monthly in about 48 healthy volunteers. The successful filing...

Read the full 120 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >